In October, the world's largest pharmaceutical company announced it would pay $894 million to settle litigation involving two of its painkillers, which studies have shown can increase the risk of heart attack and stroke.
New York-based Pfizer Inc. still sells one of those drugs, Celebrex, which is available on the market with a comprehensive warning label. The company voluntarily withdrew the other drug, Bextra, from the market in April 2005.
But the company's t...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In




